Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major
Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension
Ventricular late potentials among thalassemia patients
Genetic polymorphisms of CYP2E1, GST, and NAT2 enzymes are not associated with risk of breast cancer in a sample of Lebanese women
Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: Report of a case
Cisplatin plus vinorelbine (PVn) as a salvage regimen for refractory breast cancer
A comparison between prophylaxis and on demand treatment for severe haemophilia
Thalassemia intermedia: Revisited
Sickle cell disease: New insights into pathophysiology and treatment
Absence of JAK2 V617F mutation in thalassemia intermedia patients
Pregnancy outcome in patients with β-thalassemia intermedia at two tertiary care centers, in Beirut and Milan
Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
New Trends in Iron Chelation: Impacting Outcomes
Validation of a reverse-hybridization StripAssay for the simultaneous analysis of common α-thalassemia point mutations and deletions
Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection
Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran
Importance of optimal dosing ≥30mg-kg-d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia
Stroke in thalassemia: A dilemma
The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis
Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: Report of a case